| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bupivacaine-induced cardiovascular collapse is a feared complication because of the difficulty in restoring stable circulation (1). Early recognition is important so that the injection of bupivacaine can be discontinued. We used an animal model of near-cardiac arrest from bupivacaine infusion to identify the sequence of hemodynamic events that precedes bupivacaine-induced cardiovascular collapse. Twelve pigs (2325 kg) were sedated with ketamine and anesthetized with halothane. Arterial blood pressure and cardiac output were measured. Bupivacaine (3.75 mg/mL) was administered at a rate of 5.73 mL/min (approximately 1 mg · kg-1 · min-1) through a central venous catheter until severe ventricular arrhythmia occurred. Blood pressure and heart rate were unchanged, but cardiac output decreased by 40% with increasing doses of bupivacaine. Calculated peripheral resistance increased by 54%. The QRS complex of the surface electrocardiogram widened, and the R-wave amplitude decreased 80%, together with the decrease in cardiac output. T-wave amplitude increased initially but returned toward baseline at the largest bupivacaine doses. The plasma concentration of bupivacaine after the infusion was 16 ± 6.8 µg/mL. Implications: The increase in vascular resistance that accompanies acute bupivacaine overdose maintains blood pressure but masks severe myocardial depression.
Systemic toxicity of local anesthetics can result from accidental intravascular injection or abnormally rapid absorption from the administration site. Cardiovascular collapse is a serious consequence of overdose with any local anesthetic, especially with bupivacaine because of the difficulty in restoring stable circulation (1). Therefore, early recognition of bupivacaine overdose is important. Hemodynamic monitoring during clinical anesthesia usually relies on measurement of blood pressure and heart rate; however, blood pressure and heart rate only show small changes when bupivacaine is administered IV to human volunteers (2,3). It is possible that more subtle cardiovascular changes provide a better indication of impending disaster. We used a porcine model of near-cardiac arrest to elucidate the sequence of hemodynamic events that herald bupivacaine-induced cardiovascular collapse.
We performed this study in 12 farm-bred male pigs (2325 kg). The protocol was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. The animals were sedated with ketamine (16 mg/kg IM), then anesthetized with halothane (0.5%0.8%, end-tidal). The halothane concentration varied among animals but was constant in each animal before and during the bupivacaine infusion. The pigs' tracheas were intubated through a surgical tracheotomy, and the lungs were ventilated with oxygen delivered by a positive-pressure respirator with 5 cm H2O positive end-expiratory pressure to maintain end-tidal CO2 at approximately 35 mm Hg, as determined by capnography. A Millar catheter was inserted into the proximal aorta via the right carotid artery to measure systemic blood pressure. Heart rate was derived from the arterial pressure signal with a cardiotachometer. A balloon-tipped pulmonary artery catheter was inserted via the right external jugular vein for measurement of pulmonary artery wedge pressure. A catheter was inserted into the left carotid artery and advanced into the arch of the aorta to provide blood samples for determination of arterial bupivacaine concentrations and blood gases. A triple-lumen catheter was inserted into the right atrium via the left external jugular vein for the infusion of isotonic sodium chloride solution (5 mL · kg-1 · h-1) and for the infusion of bupivacaine through separate ports. The heart was exposed through a midline sternotomy, and the pericardium was opened. An appropriately sized flow probe with a snug fit was placed around the proximal aorta for measurement of aortic flow with an electromagnetic flowmeter, which was calibrated by the timed collection of blood after the experiment. The electrocardiogram (ECG) was recorded from subcutaneous needle electrodes inserted into the extremities using an amplifier with a low-frequency cutoff at 0.3 Hz and a high-frequency cutoff at 50 Hz. Metocurine was used for muscle relaxation. Body temperature was maintained at approximately 39°C by using a heating pad. These preparations lasted approximately 2 h after the induction of anesthesia. In the experimental protocol, bupivacaine 3.75 mg/mL was continuously infused via the central venous line at 5.73 mL/min (approximately 1 mg · kg-1 · min-1) while blood pressure, heart rate, aortic flow, pulmonary capillary wedge pressure, and ECG (lead II) were monitored continuously. The infusion was stopped when ventricular arrhythmias started. Pilot experiments had demonstrated that the animals could not be resuscitated from larger doses of bupivacaine. The animals in this study were resuscitated, then used in a separate protocol. Hemodynamic variables and ECG were recorded with a polygraph and stored on magnetic tape for later analysis. A singe blood sample to determine the bupivacaine concentration was drawn from each animal just after the infusion was stopped. Blood was collected in heparinized tubes and centrifuged, and the resulting plasma was frozen at -20°C until bupivacaine assays were performed. Bupivacaine concentrations in plasma were measured by using high-performance liquid chromatography, using an ultraviolet detector operating at a wavelength of 210 nm. The sensitivity of the assay was <0.1 µg/mL; the interday coefficient of variation at 10 µg/mL was <3% (4). Values of systolic, diastolic, and mean arterial pressure, heart rate, pulmonary capillary wedge pressure, peak aortic flow, mean aortic flow, and ECG amplitude and intervals were extracted from the oscillograph record. Values at baseline and after each 10 mL of bupivacaine had been infused (but not at the very end of infusion) were entered into a computer for analysis using a standard statistical package. Data were averaged at each time point, and variance was expressed as the standard deviation of the mean. Total peripheral resistance was calculated as the quotient of mean arterial pressure and cardiac output. Linear regression analysis was used to test the relationship between the elements of ECG morphology, such as R-wave amplitude and cardiac output, in each animal. The hemodynamic and electrophysiologic values during the administration of bupivacaine were tested for significance against baseline values by using one-way analysis of variance with linear contrasts. A P value <0.05 was considered significant.
Blood pressure and heart rate were relatively unaffected, despite sufficient direct myocardial depression by bupivacaine to decrease cardiac output 40% (P < 0.001) (Table 1). Peripheral vasoconstriction, manifest as an increase in total peripheral resistance (P < 0.001), maintained blood pressure despite the decrease in cardiac output.
In contrast, the effect of bupivacaine on the ECG was impressive (Table 1, Fig. 1). R-wave amplitude decreased progressively during the bupivacaine infusion (P < 0.001), and QRS broadened (P < 0.001). T-wave amplitude increased initially but returned toward baseline at the largest bupivacaine doses (Table 1, Fig. 2).
R-wave amplitude was correlated with the decrease in cardiac output. Regression analysis found an average correlation coefficient of 0.90 ± 0.06 for the relationship. The concentration of bupivacaine in the animals' plasma was 16.0 ± 6.8 µg/mL 30 s after the infusion. No gross motor evidence of seizure activity was noted in these halothane-anesthetized, paralyzed animals. Arterial blood gas analysis showed pH 7.41 ± 0.04, PCO2 36 ± 4 mm Hg, and PO2 315 ± 66 mm Hg at the start of bupivacaine infusion.
We performed this study with the objective of identifying an early warning sign of bupivacaine overdose. This was achieved through an analysis of the changes that take place in hemodynamic and electrophysiologic variables during the IV infusion of the drug. Bupivacaine caused no significant changes in blood pressure, despite a 41% decrease in cardiac output, because of a simultaneous increase in peripheral resistance. The QRS complex of the surface ECG widened with increasing doses of bupivacaine, and the R-wave amplitude decreased. These ECG changes were closely correlated with the decrease in cardiac output.
Assumptions We assumed that the residual effect of ketamine given at induction was small during the experimental protocol. The animals used in the study were anesthetized with halothane, and we assumed that the effect of this anesthetic on the results are predictable. Halothane certainly depresses ventricular contractility dose-dependently, and it may have augmented the depression from bupivacaine (5), although these anesthetics act through different mechanisms. The animals were anesthetized with small-dose halothane (0.6% end-tidal); thus, a major contribution to the myocardial depression resulting from bupivacaine seems unlikely. Halothane alone has little effect on intraventricular conduction (6), a major determinant of ECG morphology. Although an adverse interaction between bupivacaine and halothane on intraventricular conduction in dogs has been reported (5), an altered cardiac output or bupivacaine clearance seems to be a more likely explanation for these results than a true pharmacodynamic interaction. Thus, we assumed that alterations in QRS morphology were the result of bupivacaine alone. We measured bupivacaine concentrations only at the end of the experiment. We assumed that plasma levels increased as the infusion progressed. However, it is unlikely that the constant infusion produced a linear increase in bupivacaine concentrations because cardiac output decreased simultaneously. Thus, the bupivacaine concentration in the central compartment probably increased more rapidly at the end of the infusion. No gross motor evidence of seizure activity was noted in these halothane-anesthetized animals; however, it is possible that seizure activity occurred but was not apparent because the animals were paralyzed. Seizures might well have influenced the hemodynamic changes we observed. However, we assumed that this was not the case. Rutten et al. (7) reported that convulsive doses of bupivacaine (1 mg/kg) in awake sheep caused a marked increase in heart rate, arterial pressure, cardiac output, and myocardial contractility. There were no sudden increases in these variables during our experiment, which suggests no major effect on cardiovascular control centers. Bernards et al. (8) studied pigs and did not observe convulsions until a plasma bupivacaine concentration of 18.4 ± 3.9 µg/mL was reached. This concentration is higher than that used in the present study. Badwell et al. (9) administered bupivacaine 1.0 mg · kg-1 · min-1 to young pigs anesthetized with halothane until cardiac arrest occurred and did not observe seizures.
Interpretation Vasoconstriction mediated by bupivacaine occurs in arterioles of rat cremaster muscle (12) and rat portal vein (13). Jorfeldt et al. (14) demonstrated a 20%40% increase in systemic resistance in humans at a plasma bupivacaine concentration of approximately 2 µg/mL, which is considerably lower than the concentrations used in our study. Hogan et al. (15) examined the direct effects of bupivacaine on splanchic capacitance vessels and demonstrated significant constriction with the same concentration used in our study. The mechanism for vessel constriction with bupivacaine is not known. Although all calculated resistance values increased during the administration of bupivacaine in the present study, this might not occur in a model involving complete cardiac arrest because tissue hypoxia would tend to cause arterial vasodilation. Both central and peripheral mechanisms have been proposed for bupivacaine's cardiotoxicity (10,1617). The direct administration of small amounts of bupivacaine into the lateral cerebral ventricle (which affects the vasomotor centers of the hypothalamus and medulla) causes cardiac dysrhythmias (16). Direct effects on cardiac contractility and conduction have been demonstrated by the intracoronary injection of bupivacaine (10,17). This dose-dependent depression of contraction results in a decrease in systolic wall thickening (10). The change we observed in QRS morphology likely results from bupivacaine's effect on the conduction system of the heart. Bupivacaine impairs intracardiac electrical conduction, even at relatively slow heart rates, by causing sustained blockade of sodium channels (18). A decrease in the maximal rate of depolarization has been observed in canine Purkinje fibers (19,20). Impulse conduction time is prolonged in all parts of the heart (21). These effects result in a "smearing" of the QRS complex, with a resulting decrease in R-wave amplitude on the surface ECG. A second possible reason for decreased R-wave amplitude is an increase in ventricular size. Coyle et al. (22) reported significant dilation of the right ventricle during a bupivacaine infusion and severe conduction changes as the toxic episode progressed. A close inverse relationship between end-diastolic ventricular volume and R-wave amplitude has been shown in patients with enlarged hearts (23). In our study, bupivacaine increased T-wave amplitude at all but the largest dose, but the response was more variable than the change in R-wave amplitude. In cats, IV bupivacaine (1.4 mg/kg) caused T-wave elevation 13 s after the injections (24), and in children, intravascular bupivacaine with epinephrine caused increased T-wave amplitude (25). This study supports our contention that the ECG should be watched closely during a bupivacaine injection.
Limitations We conclude that the arterial blood pressure is a misleading guide to cardiovascular status during bupivacaine overdose in pigs. R-wave amplitude of the ECG may be a better indicator of an impending cardiac arrest. Clinically, we might be able to discover an intravascular injection by closely observing the ECG for changes in morphology of the QRS complex, immediately halt the injection, and thus prevent profound bupivacaine intoxication.
We thank Carl Lynch III, MD, PhD, for kindly reviewing the manuscript and Kraig Stetzer, BS, for his skillful technical assistance.
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|